ELDN · Eledon Pharmaceuticals Inc
United States · RS rating 17 · As of 2026-10-14
| Price | 2.25 USD |
|---|---|
| 1-day change | -3.9% |
| RS rating (overall / 1M / 3M / 12M) | 17 / 14 / 7 / 28 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 25 / 30 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +18.2% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +48.4% |
| Market cap (USD) | $285.9M |